Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
41.26 USD | -0.72% | -4.19% | -13.45% |
May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.45% | 3.45B | |
+3.18% | 108B | |
+10.32% | 105B | |
+1.57% | 23.46B | |
-13.05% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.89% | 17.19B | |
+5.78% | 13.99B | |
+36.43% | 12.53B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Wedbush Trims Ultragenyx Pharmaceutical's PT to $47 From $49, Keeps Neutral Rating